Trial Profile
A Pharmacokinetic/Pharmacodynamic phase IIb study of Ibutamoren in Pediatric Growth Hormone Deficiency (PGHD)
Status:
Planning
Phase of Trial:
Phase II
Latest Information Update: 20 Aug 2020
Price :
$35
*
At a glance
- Drugs Ibutamoren (Primary)
- Indications Somatotropin deficiency
- Focus Therapeutic Use
- 13 Aug 2020 According to a Lumos Pharma media release, this study is anticipated to begin by Q1 2021.
- 13 Aug 2020 According to a Lumos Pharma media release, this study will run in parallel with first phase 2b trial with the intention that the data will be supportive in any future regulatory filings.
- 06 Jun 2017 New trial record